Agree
does not give treatment for cancer or advise patients on their treatment plans. Anyone in doubt about their own or cancer should seek medical advice from a qualified healthcare professional.
PlaceHolder
MORE
and Oncotype – Delivering Precision Medicine
Watch how continues to transform cancer care around the world.
VIDEO
It is our mission to transform treatment decisions and outcomes in cancer by delivering clinically actionable diagnostics and services for patients.
MORE
Kim Popovits discusses devising personalized medicine in the treatment of breast cancer and colon cancer.
VIDEO
Our portfolio of tests is aimed at delivering intelligence that optimizes treatment decisions throughout the cancer patient journey.
MORE
Hear how breast cancer survivors personalized their cancer treatment with Oncotype DX.
VIDEO
is driven by the commitment to improving the lives of cancer patients.
MORE
Your Prostate Your Decision: Interview with Dan
Dan was diagnosed with early-stage prostate cancer. Watch Dan talk about his experience with the Oncotype prostate cancer test.
VIDEO
Inspired by the Life, changing work that we do? Be a part of the world's leading provider of cancer diagnostic tests.
MORE
The Brand and Company Mission
Watch Kim Popovits and others discuss the motivation, inspiration, and rewards of working at Health, as well as the company’s vision for the future.
VIDEO
Toggle Search✖
Life, changing.
More than 1 million cancer patients worldwide have used our Oncotype tests to personalize treatments and improve outcomes.
Our Mission
Health’s mission is to transform treatment decisions and outcomes in cancer by delivering clinically actionable diagnostics and services.
MORE
Oncotype IQ
Our portfolio of tests and services is aimed at delivering intelligence that optimizes treatment decisions and outcomes throughout the cancer patient journey.
MORE
Over One Million Patients Tested
In collaboration with physicians around the world, we have delivered more than 1 million Oncotype tests to cancer patients worldwide since we made our first test available to patients in 2004.
MORE
Making An Impact
is leading in the precision medicine revolution to eliminate the "one-size-fits-all" approach to cancer treatment.
Our Pipeline
MORE
TAILORx: Transforming the Treatment of Breast Cancer
Landmark TAILORx results demonstrate that the Oncotype Breast Recurrence Score Test definitively identifies the 70% of women with early-stage breast cancer who receive no benefit from chemotherapy, and the 30% of women for whom chemotherapy benefit can be life-saving.
VIDEO
World Class Commercial Channel
We deliver over 400 Oncotype test results per day to more than 90 countries through our centralized clinical laboratory, serving physicians and patients with our industry-leading customer service team and more than 200 sales and managed care representatives around the world.
MORE
Broadening Reimbursement for Patients Worldwide
is dedicated to securing reimbursement to ensure cancer patients around the world have access to our clinically actionable Oncotype tests. Outside the U.S., there are over 260 million lives covered and growing. The Oncotype prostate cancer test is now covered by Medicare in the for qualified patients, giving nearly 60,000 prostate cancer patients the opportunity to personalize their cancer treatment.
MORE
Our expertise consistently demonstrates to physicians, patients and payors that our tests are improving treatment decisions and outcomes, providing significant benefit from both a care and cost perspective.
MORE
“testing helped me make my decision. would advise anybody to get all the information you can before you make a decision about your life and your body.”
Jim G.
MORE
Our People
Employees on the Company's Higher Purpose
© 2019 Health, All rights reserved.
© 2019 Health, All rights reserved.
In the and certain other jurisdictions, Health, Oncotype DX, Oncotype IQ, and Recurrence Score are registered trademarks, and Prostate Score, and AR-V7 Nucleus Detect are pending registered trademarks, of Health, Inc.
© 2019 Health, All rights reserved.Agree
does not give treatment for cancer or advise patients on their treatment plans. Anyone in doubt about their own or cancer should seek medical advice from a qualified healthcare professional.
PlaceHolder
Toggle navigation
MENU
ARE
DO
PRODUCTS
HELP
TEAM
Investors
Newsroom
Resources
Portal Login
ARE
BACK
Overview
Our Mission
Company Timeline & Milestones
Leadership
Our Founders
Contact Us
DO
BACK
Overview
Clinical Leadership
World Class Commercial Channel
Patient Advocacy
PRODUCTS
BACK
Overview
Oncotype DX
Oncotype for Breast Cancer
Oncotype for Prostate Cancer
Oncotype for Colon Cancer
Our Product Pipeline
HELP
BACK
Overview
TEAM
BACK
Overview
Benefits
International Benefits
United States - English
BACK
United States - English
Deutschland - Deutsch
France - Français
Italia - Italiano
Japan - Japanese
United Kingdom - English
Investors
Newsroom
Resources
Portal Login
United States - English
Deutschland - Deutsch
France - Français
Italia - Italiano
Japan - Japanese
United Kingdom - English
Toggle navigation
ARE
DO
PRODUCTS
HELP
TEAM
is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today.
MORE
Overview
Our Mission
Company Timeline & Milestones
Leadership
Our Founders
Contact Us
and Oncotype – Delivering Precision Medicine
Watch how continues to transform cancer care around the world.
VIDEO
It is our mission to transform treatment decisions and outcomes in cancer by delivering clinically actionable diagnostics and services for patients.
MORE
Overview
Clinical Leadership
World Class Commercial Channel
Patient Advocacy
Individual Molecular Fingerprint of Tumors
Kim Popovits discusses devising personalized medicine in the treatment of breast cancer and colon cancer.
VIDEO
Our portfolio of tests is aimed at delivering intelligence that optimizes treatment decisions throughout the cancer patient journey.
MORE
Overview
Oncotype DX
Oncotype for Breast Cancer
Oncotype for Prostate Cancer
Oncotype for Colon Cancer
Our Product Pipeline
Not All Breast Cancer is the Same. Get Your Oncotype Score.
Hear how breast cancer survivors personalized their cancer treatment with Oncotype DX.
VIDEO
is driven by the commitment to improving the lives of cancer patients.
MORE
Overview
Your Prostate Your Decision: Interview with Dan
Dan was diagnosed with early-stage prostate cancer. Watch Dan talk about his experience with the Oncotype prostate cancer test.  
VIDEO
Inspired by the Life, changing work that we do? Be a part of the world's leading provider of cancer diagnostic tests.
MORE
Overview
Benefits
International Benefits
The Brand and Company Mission
Watch Kim Popovits and others discuss the motivation, inspiration, and rewards of working at Health, as well as the company’s vision for the future.
VIDEO
Toggle Search
✖
Select the group you would like to contact:
Business Development
Compliance
Contracts/Licensing
General Legal
Government & Regulatory Affairs 
Intellectual Property
Investor Relations
Main Lobby (U.S.) 
Media Relations
Media Relations (Asia, Europe, Latin America)
Patient Advocacy
Website Comments
───────────────────────
Customer Service
Business Development
Email: 
Compliance
Email: 
Contracts/Licensing
Email: 
General Legal
Email: 
Government & Regulatory Affairs
Email: 
Intellectual Property
Email: 
Investor Relations
Tel: +1 (650) 569-2281
Email: 
Main Lobby (U.S.)
101 Galveston Drive
Tel: 
+1 (650) 556-9300
Media Relations
Victoria Steiner
Tel: 
+1 (650) 569-2499
Email: 
Media Relations (Asia, Europe, Latin America)
Federico Maiardi
Tel: 
+41-227-152-921
Email: 
Patient Advocacy
Email: 
Website Comments
Email: 
Customer Service
If you have a question about one of our tests or about a specific order, submit your inquiry on 
.
Contact Me:
Name
name is required.
Email
An email is required.
Invalid Email
Phone
Invalid Phone Number. Please format like 1-650-556-9300 or +123(45)678-910.
Preferred Method of Contact
Email
Phone
SUBMIT
We respect your privacy.
Guest Entrance & Main Lobby
General Mailing & Overnight Delivery Address 
Health, Inc.
Who We Are
Our Mission
Company Timeline & Milestones
Leadership
Our Founders
Contact Us
Follow Us
Connect with us and get the latest news on genomics and transforming cancer care.
WHAT'NEW
Meet Vilma
Find out how she dealt with her node-positive breast cancer.
STORY
Meet Vilma
Find out how she dealt with her node-positive breast cancer.
STORY
Meet Vilma
Find out how she dealt with her node-positive breast cancer.
STORY
Follow Us
Connect with us and get the latest news on genomics and transforming cancer care.
WHAT'NEW
Follow Us
Connect with us and get the latest news on genomics and transforming cancer care.
WHAT'NEW
Who We Are
Our Mission
Timeline & Milestones
Leadership
Contact Us
Who We Help
What We Do
Clinical Leadership
Commercial Channel
Patient Advocacy
Join Our Team
Careers
Benefits
International Benefits
Oncotype Products
Oncotype DX
For Breast Cancer
For Prostate Cancer
For Colon Cancer
Our Product Pipeline
Newsroom
Press Releases
Media Resources
Social Hub
In the News
Investors
Resources
Videos
Patient Resources
Publications & Guidelines
Abstracts
Grants & Contributions
Glossary
Licenses & Accreditations
Privacy Policy
Terms & Conditions
Licenses & Accreditations
Privacy Policy
Terms & Conditions
© 2019 Health, All rights reserved.
© 2019 Health, All rights reserved.
In the and certain other jurisdictions, Health, Oncotype DX, Oncotype IQ, and Recurrence Score are registered trademarks, and Prostate Score, and AR-V7 Nucleus Detect are pending registered trademarks, of Health, Inc. 
© 2019 Health, All rights reserved.
In the and certain other jurisdictions, Health, Oncotype DX, Oncotype IQ, and Recurrence Score are registered trademarks, and Prostate Score, and AR-V7 Nucleus Detect are pending registered trademarks, of Health, Inc. Agree
does not give treatment for cancer or advise patients on their treatment plans. Anyone in doubt about their own or cancer should seek medical advice from a qualified healthcare professional.
PlaceHolder
Toggle navigation
MENU
ARE
DO
PRODUCTS
HELP
TEAM
Investors
Newsroom
Resources
Portal Login
ARE
BACK
Overview
Our Mission
Company Timeline & Milestones
Leadership
Our Founders
Contact Us
DO
BACK
Overview
Clinical Leadership
World Class Commercial Channel
Patient Advocacy
PRODUCTS
BACK
Overview
Oncotype DX
Oncotype for Breast Cancer
Oncotype for Prostate Cancer
Oncotype for Colon Cancer
Our Product Pipeline
HELP
BACK
Overview
TEAM
BACK
Overview
Benefits
International Benefits
United States - English
BACK
United States - English
Deutschland - Deutsch
France - Français
Italia - Italiano
Japan - Japanese
United Kingdom - English
Investors
Newsroom
Resources
Portal Login
United States - English
Deutschland - Deutsch
France - Français
Italia - Italiano
Japan - Japanese
United Kingdom - English
Toggle navigation
ARE
DO
PRODUCTS
HELP
TEAM
is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today.
MORE
Overview
Our Mission
Company Timeline & Milestones
Leadership
Our Founders
Contact Us
and Oncotype – Delivering Precision Medicine
Watch how continues to transform cancer care around the world.
VIDEO
It is our mission to transform treatment decisions and outcomes in cancer by delivering clinically actionable diagnostics and services for patients.
MORE
Overview
Clinical Leadership
World Class Commercial Channel
Patient Advocacy
Individual Molecular Fingerprint of Tumors
Kim Popovits discusses devising personalized medicine in the treatment of breast cancer and colon cancer.
VIDEO
Our portfolio of tests is aimed at delivering intelligence that optimizes treatment decisions throughout the cancer patient journey.
MORE
Overview
Oncotype DX
Oncotype for Breast Cancer
Oncotype for Prostate Cancer
Oncotype for Colon Cancer
Our Product Pipeline
Not All Breast Cancer is the Same. Get Your Oncotype Score.
Hear how breast cancer survivors personalized their cancer treatment with Oncotype DX.
VIDEO
is driven by the commitment to improving the lives of cancer patients.
MORE
Overview
Your Prostate Your Decision: Interview with Dan
Dan was diagnosed with early-stage prostate cancer. Watch Dan talk about his experience with the Oncotype prostate cancer test.  
VIDEO
Inspired by the Life, changing work that we do? Be a part of the world's leading provider of cancer diagnostic tests.
MORE
Overview
Benefits
International Benefits
The Brand and Company Mission
Watch Kim Popovits and others discuss the motivation, inspiration, and rewards of working at Health, as well as the company’s vision for the future.
VIDEO
Toggle Search
✖
Our Mission
See why is the global leader in the translation and delivery of practice-changing cancer information.
MORE
Company Timeline and Milestones
It all started with a close friend’s cancer diagnosis. Follow the story of how revolutionized the treatment of cancer.
MORE
Leadership
MORE
Who We Are
Our Mission
Timeline & Milestones
Leadership
Contact Us
Who We Help
What We Do
Clinical Leadership
Commercial Channel
Patient Advocacy
Join Our Team
Careers
Benefits
International Benefits
Oncotype Products
Oncotype DX
For Breast Cancer
For Prostate Cancer
For Colon Cancer
Our Product Pipeline
Newsroom
Press Releases
Media Resources
Social Hub
In the News
Investors
Resources
Videos
Patient Resources
Publications & Guidelines
Abstracts
Grants & Contributions
Glossary
Licenses & Accreditations
Privacy Policy
Terms & Conditions
Licenses & Accreditations
Privacy Policy
Terms & Conditions
© 2019 Health, All rights reserved.
© 2019 Health, All rights reserved.
In the and certain other jurisdictions, Health, Oncotype DX, Oncotype IQ, and Recurrence Score are registered trademarks, and Prostate Score, and AR-V7 Nucleus Detect are pending registered trademarks, of Health, Inc. 
© 2019 Health, All rights reserved.
In the and certain other jurisdictions, Health, Oncotype DX, Oncotype IQ, and Recurrence Score are registered trademarks, and Prostate Score, and AR-V7 Nucleus Detect are pending registered trademarks, of Health, Inc. Agree
does not give treatment for cancer or advise patients on their treatment plans. Anyone in doubt about their own or cancer should seek medical advice from a qualified healthcare professional.
PlaceHolder
MORE
and Oncotype – Delivering Precision Medicine
Watch how continues to transform cancer care around the world.
VIDEO
It is our mission to transform treatment decisions and outcomes in cancer by delivering clinically actionable diagnostics and services for patients.
MORE
Kim Popovits discusses devising personalized medicine in the treatment of breast cancer and colon cancer.
VIDEO
Our portfolio of tests is aimed at delivering intelligence that optimizes treatment decisions throughout the cancer patient journey.
MORE
Hear how breast cancer survivors personalized their cancer treatment with Oncotype DX.
VIDEO
is driven by the commitment to improving the lives of cancer patients.
MORE
Your Prostate Your Decision: Interview with Dan
Dan was diagnosed with early-stage prostate cancer. Watch Dan talk about his experience with the Oncotype prostate cancer test.
VIDEO
Inspired by the Life, changing work that we do? Be a part of the world's leading provider of cancer diagnostic tests.
MORE
The Brand and Company Mission
Watch Kim Popovits and others discuss the motivation, inspiration, and rewards of working at Health, as well as the company’s vision for the future.
VIDEO
Toggle Search✖
Experienced Leadership Committed to Delivering Results
Meet Our Executive Team and Board of Directors| Health, Inc.
Health's team has extensive experience in a variety of cutting-edge technical fields including the molecular diagnostics, information technology, biotechnology, pharmaceutical and industries. Team members have demonstrated continued success in starting businesses, researching and developing novel drugs, launching products, building successful organizations and delivering value to shareholders.
Management Team
Filter by
Management Team
Kimberly Popovits
Bradley Cole
Chief Financial Officer
Steven Shak, M.D.
Jon Cassel, Ph.D.
Julian Baker, Managing Partner, Lead Independent Director, Baker Brothers Investments
Julian Baker has served as a director of since January 2001. Mr. Baker is a managing partner of Baker Brothers Investments, which he and his brother, Felix Baker, Ph.D., founded in 2000. Mr. Baker’s firm manages a family of long-term investment funds for major university endowments and foundations, which are focused on publicly traded life sciences companies. Mr. Baker’s career as a fund manager began in 1994 when he co-founded a biotechnology investing partnership with the Tisch Family, now known as Baker/Tisch investments. Previously, Mr. Baker was employed from 1988 to 1993 by the private equity investment arm of Credit Suisse First Boston Corporation. He is also a director of Incyte Corporation, Neurogen Corporation, Theravance, Inc. and Trimeris, Inc. Mr. Baker holds a Bachelor of Arts in Social Studies from Harvard University.
Felix Baker, Ph.D., Managing Partner, Baker Brothers Investments
Felix Baker, Ph.D., has served as a director of since 2012.  Felix Baker is a Managing Partner of Baker Brothers Investments, which he and his brother, Company director Julian Baker, founded in 2000. Dr. Baker’s firm manages a family of long-term investment funds for major university endowments and foundations, which are focused on publicly traded life sciences companies. Dr. Baker’s career as a fund-manager began in 1994 when he co-founded a biotechnology investing partnership with the Tisch Family. Dr. Baker holds a Bachelor of Science and a Ph.in Immunology from Stanford University, where he also completed two years of medical school. Dr. Baker currently serves as a director of Seattle Genetics, Inc. and Synageva BioPharma Corp., both of which are publicly-traded biotechnology companies.
Fred Cohen, M.D., D.Phil., Senior Managing Director, Vida Ventures
Fred Cohen, M.D., D.Phil., has served as a director of since April 2002. Dr. Cohen is a senior managing director at Vida Ventures. Prior to that he was a senior advisor to where he served as a partner and founder of Biotechnology from 2001 to 2016. Dr. Cohen was a Professor of Medicine and Pharmacology at the University of California, San Francisco, where he taught from 1998 to 2014. Dr. Cohen serves as a director of BioCryst Pharmaceuticals, Inc., CareDx, Inc., FivePrime Therapeutics, Inc., Quintiles Transnational Holdings, Inc., Tandem Diabetes Care, Inc., Veracyte, Inc. and other privately held companies. Dr. Cohen holds a Bachelor of Science degree in Molecular Biophysics and Biochemistry from Yale University, a D.Phil. in Molecular Biophysics from Oxford University and an degree from Stanford University.
Henry Fuchs, M.D., President, Worldwide Research & Development, BioMarin Pharmaceutical Inc.
Henry Fuchs, M.D, has served as a director of since September 2013. Dr. Fuchs is the President of Worldwide Research and Development at BioMarin Pharmaceutical Inc., a biopharmaceutical company. From September 2005 to December 2008, Dr. Fuchs was Executive Vice President and Chief Medical Officer of Onyx Pharmaceuticals, Inc., a biopharmaceutical company. From October 1996 until June 2005, Dr. Fuchs served in multiple roles of increasing responsibility at Ardea Biosciences, Inc., a biotechnology company, first as Vice President, Clinical Affairs, then as President and Chief Operating Officer, and finally as President and Chief Executive Officer. From 1987 to 1996, Dr. Fuchs held various positions at Genentech Inc., a biotechnology company. Dr. Fuchs serves as a director of Mirati Therapeutics, Inc. and served as a director of Ardea Biosciences, Inc. from November 2001 to June 2012. Dr. Fuchs received a Bachelor of Arts degree in Biochemical Sciences from Harvard University, and an degree from George Washington University.
Ginger Graham, Former President and CEO, Amylin Pharmaceuticals
Ginger Graham has served as a director of since 2008.  Ms. Graham is a member of the Harvard Business School Industry Alumni Advisory Board, The University of Arkansas Chancellor’s Campaign Steering Committee, and the Advisory Board for the BioFrontiers Institute at the University of Colorado.  She is also a director of Walgreen Co., the Proteus Digital Pharmaceutical Division, Surefire Medical, Elcelyx Therapeutics, and the Circle of Life Hospice Foundation.  Ms. Graham serves on the Advisory Board for the Kellogg Center for Executive Women and co-chairs the Scientific Council of the University of Colorado’s Center for Women’s Research.
Geoffrey Parker, Chief Financial Officer and Senior Vice President, Tricida, Inc.
Geoffrey Parker has served as a director of since June 2016. He is currently Chief Financial Officer and Senior Vice President at Tricida, Inc. and a member of the board of directors at ChemoCentryx, Inc, Perrigo Company plc and Sunesis Pharmaceuticals, Inc. Prior to that, Mr. Parker was the Executive Vice President of Anacor Pharmaceuticals, Inc. from May 2014 to May 2015. Additionally, he was the Chief Financial Officer of Anacor Pharmaceuticals, Inc. from September 2010 to May 2015. Mr. Parker served as the Vice President, Managing Director and Partner at the global investment banking and securities firm Goldman, Sachs & Co., leading their West Coast Healthcare Investment Banking practice from April 1997 to April 2009. From 1995 to 1997, Mr. Parker was Vice President at Feibusch & Co., a venture capital firm in Larkspur, California. Mr. Parker received an from Dartmouth College in Engineering Sciences and Economics and an from the Stanford Graduate School of Business.
Kimberly Popovits, Chairman of the Board, Chief Executive Officer & President
Committed to changing the paradigm of cancer care, Kim Popovits has led in revolutionizing the treatment of cancer through genomic-based diagnostic tests for breast, colon and prostate cancers that personalize and optimize treatment decisions. Kim has served as Health's Chairman of the Board since 2012, and Chief Executive Officer and President since 2009. She was President and Chief Operating Officer since joining the company in 2002. Prior to joining Health, Kim served as Senior Vice President, Marketing and Sales at the biotechnology company, Genentech, Inc. During her 15 years at Genentech, Kim led the successful commercialization of 14 new therapies, including Herceptin®, the revolutionary targeted treatment that changed the way doctors treat a particularly aggressive form of breast cancer. Kim currently serves on the boards of the California Life Sciences Association (CLSA), the Personalized Medicine Coalition (PMC), the American Clinical Laboratory Association (ACLA), and MyoKardia. Kim is also the President of The Coalition for 21st Century Medicine. Kim's contributions to the science and commercialization of the biotechnology industry have been acknowledged by multiple organizations including being named Most Admired in 2014 and one of the Forever Influential Women in the Bay Area from by the San Francisco Business Times. She was also named Woman of the Year by Women Care Executives in 2008, received the Ferolyn Powell Leadership Award from MedTechWomen in 2016, and received the Salute to Excellence Award from the American Liver Foundation in 2017. Kim holds a Bachelor of Arts degree in Business from Michigan State University.
Lee Anderson, Vice President, Oncology Sales
Frederick Baehner, M.D., Vice President and Chief Medical Officer
Rolando Brawer, Vice President, Corporate Development
Calvin Chao, Vice President, Global Medical Affairs
Irene Chen, Vice President, Clinical Lab Operations
Emily Faucette, Vice President, Corporate Communications & Investor Relations
David Green, Vice President and Chief Information Officer
Darrell Moore, Vice President, Global Total Rewards and Operations
Franco Palomba, Vice President, Finance
Donna Polizio, Vice President, Managed Care & Reimbursement
Jonathan Truelove, Vice President, General Counsel, International
Jim Whitmore, Vice President, Biostatistics & Data Management
MORE
The Brand and Company Mission
Watch Kim Popovits and others discuss the motivation, inspiration and rewards of working at Health, as well as the company's vision for the future.
VIDEO
The Brand and Company Mission
Watch Kim Popovits and others discuss the motivation, inspiration and rewards of working at Health, as well as the company's vision for the future.
VIDEO
The Brand and Company Mission
Watch Kim Popovits and others discuss the motivation, inspiration and rewards of working at Health, as well as the company's vision for the future.
VIDEO
Follow Us
Connect with us and get the latest news on genomics and transforming cancer care.
MORE
Follow Us
Connect with us and get the latest news on genomics and transforming cancer care.
MORE
© 2019 Health, All rights reserved.
© 2019 Health, All rights reserved.
In the and certain other jurisdictions, Health, Oncotype DX, Oncotype IQ, and Recurrence Score are registered trademarks, and Prostate Score, and AR-V7 Nucleus Detect are pending registered trademarks, of Health, Inc.
© 2019 Health, All rights reserved.Agree
does not give treatment for cancer or advise patients on their treatment plans. Anyone in doubt about their own or cancer should seek medical advice from a qualified healthcare professional.
PlaceHolder
MORE
and Oncotype – Delivering Precision Medicine
Watch how continues to transform cancer care around the world.
VIDEO
It is our mission to transform treatment decisions and outcomes in cancer by delivering clinically actionable diagnostics and services for patients.
MORE
Kim Popovits discusses devising personalized medicine in the treatment of breast cancer and colon cancer.
VIDEO
Our portfolio of tests is aimed at delivering intelligence that optimizes treatment decisions throughout the cancer patient journey.
MORE
Hear how breast cancer survivors personalized their cancer treatment with Oncotype DX.
VIDEO
is driven by the commitment to improving the lives of cancer patients.
MORE
Your Prostate Your Decision: Interview with Dan
Dan was diagnosed with early-stage prostate cancer. Watch Dan talk about his experience with the Oncotype prostate cancer test.
VIDEO
Inspired by the Life, changing work that we do? Be a part of the world's leading provider of cancer diagnostic tests.
MORE
The Brand and Company Mission
Watch Kim Popovits and others discuss the motivation, inspiration, and rewards of working at Health, as well as the company’s vision for the future.
VIDEO
Toggle Search✖
Our Mission
Our Mission to Transform Treatment Outcomes in Cancer | Health, Inc.
World’s Leading Provider of Genomic-Based Tests for Personalizing Cancer Care
Our Mission: To transform treatment decisions and outcomes in cancer by delivering clinically actionable diagnostics and services for patients.
Our Vision: To revolutionize the treatment of cancer throughout the patient journey.
is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today. The company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of massive amounts of data into clinically-actionable results for treatment planning throughout the cancer patient's journey, from diagnosis to treatment selection and monitoring.
Founded in 2000, is committed to improving the quality of cancer treatment decision making through the research, development and commercialization of genomic-based clinical laboratory services. The company conducts sophisticated research to develop clinically validated molecular diagnostic tests that provide individualized information on the likelihood of cancer disease recurrence, and — in some cases — response to certain types of therapy.
developed and follows a highly specialized process that adheres to applicable global regulations and standards, including (Clinical Laboratory Improvement Amendments) regulations and (College of American Pathologists) in the to deliver the highest standards of quality and proficiency testing.
Learn more about Leadership
See what’s behind our tests which are improving treatment decisions and providing significant benefit from both a care and cost perspective.
Our World Class Commercial Channel
We deliver over 400 Oncotype test results per day to more than 90 countries through our centralized clinical laboratory.
Join Our Team
Come join our team of passionate and exceptional people who make helping cancer patients their mission and inspiration.
MORE
The Brand and Company Mission
Watch Kim Popovits and others discuss the motivation, inspiration, and rewards of working at Health, as well as the company’s vision for the future.
VIDEO
The Brand and Company Mission
Watch Kim Popovits and others discuss the motivation, inspiration, and rewards of working at Health, as well as the company’s vision for the future.
VIDEO
The Brand and Company Mission
Watch Kim Popovits and others discuss the motivation, inspiration, and rewards of working at Health, as well as the company’s vision for the future.
VIDEO
Join Our Team
Come join our team of passionate and exceptional people who make helping cancer patients their mission and inspiration.
MORE
Join Our Team
Come join our team of passionate and exceptional people who make helping cancer patients their mission and inspiration.
MORE
© 2019 Health, All rights reserved.
© 2019 Health, All rights reserved.
In the and certain other jurisdictions, Health, Oncotype DX, Oncotype IQ, and Recurrence Score are registered trademarks, and Prostate Score, and AR-V7 Nucleus Detect are pending registered trademarks, of Health, Inc.
© 2019 Health, All rights reserved.Agree
does not give treatment for cancer or advise patients on their treatment plans. Anyone in doubt about their own or cancer should seek medical advice from a qualified healthcare professional.
PlaceHolder
MORE
and Oncotype – Delivering Precision Medicine
Watch how continues to transform cancer care around the world.
VIDEO
It is our mission to transform treatment decisions and outcomes in cancer by delivering clinically actionable diagnostics and services for patients.
MORE
Kim Popovits discusses devising personalized medicine in the treatment of breast cancer and colon cancer.
VIDEO
Our portfolio of tests is aimed at delivering intelligence that optimizes treatment decisions throughout the cancer patient journey.
MORE
Hear how breast cancer survivors personalized their cancer treatment with Oncotype DX.
VIDEO
is driven by the commitment to improving the lives of cancer patients.
MORE
Your Prostate Your Decision: Interview with Dan
Dan was diagnosed with early-stage prostate cancer. Watch Dan talk about his experience with the Oncotype prostate cancer test.
VIDEO
Inspired by the Life, changing work that we do? Be a part of the world's leading provider of cancer diagnostic tests.
MORE
The Brand and Company Mission
Watch Kim Popovits and others discuss the motivation, inspiration, and rewards of working at Health, as well as the company’s vision for the future.
VIDEO
Toggle Search✖
Our Founders
Health's Scientific Founders
In 2000, inspired by a close friend’s cancer diagnosis, Randy Scott founded in Redwood City, California with the goal of developing high-value diagnostics to enable more personalized cancer treatment decisions based on the activity within a patient’s individual tumor.
Randy Scott, Ph.D.
Randy Scott is co-founder, chairman and of Invitae Corporation (NYSE: NVTA), a company focused on bringing comprehensive genetic information into routine medical practice to improve the quality of healthcare for billions of people by making genetic testing more affordable and accessible. Prior to starting Invitae, Dr. Scott founded (NASDAQ: GHDX) in 2000 and led the company as for nine years with a focus on improving the quality of treatment decisions for patients with cancer. Dr. Scott has played a role in founding several successful biotech companies in addition to Inc., including Incyte (NASDAQ: INCY), a information company. Dr. Scott, an author of more than 40 scientific publications, 20 patents, and recipient of numerous awards, holds a Bachelor of Science degree in Chemistry from Emporia State University and a Ph.in Biochemistry from the University of Kansas.
Founder Randy Scott talks about the company's ahead-of-its-time vision and the many doubters that tried to derail what set out to do from Day 1, and has since been very success at.
Steven Shak, M.D.
Dedicated to optimizing cancer treatment outcomes and bringing the patient voice into product development, Steve Shak, has served as Co-Founder, Chief Scientific Officer since 2012 and was Chief Medical Officer from 2000 to 2013. Under Steve's leadership used innovative molecular diagnostic methods and rigorous clinical studies to develop the Oncotype breast cancer and colon cancer assays and has maintained an 80% product development success rate. Steve has been a leader in personalized medicine for more than two decades. Prior to co-founding in 2000, Steve served for 14 years in various roles in discovery research and medical affairs at Genentech, Inc., a biotechnology company dedicated to using human genetic information to discover, develop, manufacture and commercialize medicines to treat patients with serious or life-threatening medical conditions. Steve led the clinical team that gained approval for Herceptin®, a targeted biologic treatment for breast cancer. He also initiated the cancer clinical trials of the anti-angiogenesis agent, Avastin®. In addition, Steve discovered Pulmozyme®, a mucus-dissolving enzyme that is approved worldwide for the treatment of the genetic disease cystic fibrosis. Prior to joining Genentech, Steve was an Assistant Professor of Medicine and Pharmacology at New York University School of Medicine. Steve holds a Bachelor of Arts degree in Chemistry from Amherst College and an degree from New York University School of Medicine, and completed his post-doctoral training at the University of California, San Francisco.
Breast cancer patients can easily receive the Oncotype Breast Cancer Assay, according to Dr. Steven Shak of Health.
Joffre Baker, Ph.D.
Since co-founding the company in 2000, Joffre Baker, Ph.has served as Co-Founder, Senior Biology Fellow and has overseen the research and development teams behind the breast, colon and prostate cancer programs at Health. Joffre and his team are currently deploying Next Generation Sequencing technology and its application across all research initiatives in an effort to connect either gene mutations or expression profiles to clinical outcomes and provide additional personalized information to physicians and patients beyond that already available through the use of Oncotype Prior to cofounding in 2000, Joffre served as Vice President for Research Discovery at Genentech, Inc., a biotechnology company, dedicated to using human genetic information to discover, develop, manufacture and commercialize medicines to treat patients with serious or life-threatening medical conditions. From 1993 to 2000, Joffre oversaw Research Discovery at Genentech, which included the Departments of Cardiovascular Research, Oncology, Immunology, Endocrinology and Pathology. From 1991 to 1993, he served as Genentech’s Director of Cardiovascular Research. Prior to joining Genentech, Joffre was a faculty member in the Department of Biochemistry at the University of Kansas. He holds a Bachelor of Science degree in Biology and Chemistry from the University of California, San Diego and a Ph.in Biochemistry from the University of Hawaii. Joffre is the recipient of a (National Institutes of Health) Research Career Development Award (1983 – 1988), and is the author of over 65 publications.
Learn more about Leadership
See what’s behind our tests which are improving treatment decisions and providing significant benefit from both a care and cost perspective.
Oncotype Products
Turning insight into action. Learn about the power of the portfolio.
MORE
and Oncotype – Delivering Precision Medicine
Watch how continues to transform cancer care around the world.
VIDEO
and Oncotype – Delivering Precision Medicine
Watch how continues to transform cancer care around the world.
VIDEO
and Oncotype – Delivering Precision Medicine
Watch how continues to transform cancer care around the world.
VIDEO
Contact Us
We have offices worldwide to help you with your inquiries.
MORE
Contact Us
We have offices worldwide to help you with your inquiries.
MORE
© 2019 Health, All rights reserved.
© 2019 Health, All rights reserved.
In the and certain other jurisdictions, Health, Oncotype DX, Oncotype IQ, and Recurrence Score are registered trademarks, and Prostate Score, and AR-V7 Nucleus Detect are pending registered trademarks, of Health, Inc.
© 2019 Health, All rights reserved.Agree
does not give treatment for cancer or advise patients on their treatment plans. Anyone in doubt about their own or cancer should seek medical advice from a qualified healthcare professional.
PlaceHolder
MORE
and Oncotype – Delivering Precision Medicine
Watch how continues to transform cancer care around the world.
VIDEO
It is our mission to transform treatment decisions and outcomes in cancer by delivering clinically actionable diagnostics and services for patients.
MORE
Kim Popovits discusses devising personalized medicine in the treatment of breast cancer and colon cancer.
VIDEO
Our portfolio of tests is aimed at delivering intelligence that optimizes treatment decisions throughout the cancer patient journey.
MORE
Hear how breast cancer survivors personalized their cancer treatment with Oncotype DX.
VIDEO
is driven by the commitment to improving the lives of cancer patients.
MORE
Your Prostate Your Decision: Interview with Dan
Dan was diagnosed with early-stage prostate cancer. Watch Dan talk about his experience with the Oncotype prostate cancer test.
VIDEO
Inspired by the Life, changing work that we do? Be a part of the world's leading provider of cancer diagnostic tests.
MORE
The Brand and Company Mission
Watch Kim Popovits and others discuss the motivation, inspiration, and rewards of working at Health, as well as the company’s vision for the future.
VIDEO
Toggle Search✖
How We Got Here… One Patient at a Time!
Established the same year the human genome was first sequenced in 2000, was founded with a bold mission:  to harness the potential of the revolution to eliminate the “one-size-fits-all” approach to cancer treatment. Select a date below to see the history of unfold.
2018
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2001
2000
Landmark TAILORx Results Published
Independently led by the ECOG-Research Group and sponsored by the NCI, the prospective, randomized, Phase TAILORx trial results definitively identify the 70% of women with early-stage breast cancer who receieve no benefit from chemotherapy, and the 30% for whom chemotherapy benefit can be life-saving.
The first and only liquid biopsy test of its kind, the Oncotype AR-V7 Nucleus Detect test, predicts treatment response in men with metastatic castration-resistant prostate cancer (mCRPC) by accurately identifying AR-V7 protein in the tumor cell to inform treatment decisions. Read more .
Biocartis Partnership to Develop version of the Oncotype Breast Cancer Test to Broaden Global Patient Access
Exclusive agreement to develop an in vitro diagnostic (IVD) version of the Oncotype Breast Recurrence Score test on Biocartis' Idylla platform that can be performed locally by laboratory partners and in hospitals around the world.
Oncotype Intelligence Platform Helps More than 800,000 Patients Worldwide
The Oncotype portfolio of tests for invasive breast cancer, breast cancer, colon cancer, lung cancer and prostate cancer help more than 800,000 patients make more informed treatment decisions around the world.
Oncotype Intelligence Platform Helps More than 700,000 Patients Worldwide
The Oncotype portfolio of tests for invasive breast cancer, breast cancer, colon cancer, lung cancer and prostate cancer help more than 700,000 patients make more informed treatment decisions around the world.
Topline Study Results Demonstrate Oncotype Predicts Prostate Cancer Metastasis and Mortality
Oncotype Prostate Score becomes only test validated to measure all four critical features of tumor aggressiveness. Read more
Unsurpassed Amount of Prospective Clinical Outcomes Results Reinforce Oncotype DX’s Unmatched Value in Personalizing Breast Cancer Treatment
Multiple large independent studies in over 63,000 breast cancer patients across four countries highlight superior clinical evidence for Oncotype in identifying which patients with node-negative and node-positive invasive breast cancer should be treated with chemotherapy. Read more
Strategic Collaboration with Epic Sciences to Deliver AR-V7 Liquid Biopsy Test Expands Oncotype Portfolio
Exclusive agreement to commercialize Epic Sciences' novel AR-V7 liquid biopsy test to predict treatment response in metastatic prostate cancer, furthering Health’s vision to serve patients across their cancer journey. Read more
Plan Trial Reports Clinical Outcomes
One of Europe's largest contemporary adjuvant breast cancer trials conducted by the West German Study Group in Germany showed that Oncotype accurately predicted which patients can be spared chemotherapy even when traditional factors indicate higher-risk disease and their disease-free survival five years after the diagnosis. Read More
Oncotype included in German National Cancer Guidelines with 1Level of Evidence
First and only multi-gene breast cancer test to be included in German National Cancer Guidelines following publication of multiple large prospective outcomes studies. Read more
Registry Outcomes Results
Prospective outcomes results from a large population observational study in more than 44,500 breast cancer patients show that patients with Recurrence Score less than 18 have excellent breast cancer survival at five years. Read More
TailorOutcomes Results Published
Large TAILORx outcomes study demonstrates 99% of patients with low Oncotype Recurrence Score results were free of breast cancer recurrence following five years of hormone therapy alone. Read More
Clalit Services Study
Prospective clinical outcomes results from Clalit Services, the largest Maintenance Organization in Israel, reinforces ability of Oncotype to predict clinical outcomes in patients with low and intermediate Recurrence Score results. Read more
Oncotype Prostate Cancer Test Covered by Medicare
Oncotype prostate cancer test receives Medicare coverage for qualifying patients, bringing precision medicine to nearly 60,000 prostate cancer patients in the United States. Read More
Bladder Cancer Liquid Biopsy Test Advances
presents positive proof-of-concept data for bladder cancer liquid biopsy test. Read More
Patients Gain Access to Oncotype Breast Cancer Test
National Service (NHS) England agrees to access program for the Oncotype breast cancer test following NICE’s exclusive recommendation. Read More
Liquid Biopsy Pipeline Expansion
advances development of liquid biopsy-based cancer tests to detect breast and bladder cancers in blood and urine samples. Read more
Oncotype Helps More than 500,000 Patients
The Oncotype portfolio of tests for invasive breast cancer, breast cancer, colon cancer and prostate cancer help more than 500,000 patients make more informed treatment decisions around the world.
Oncotype Prostate Cancer Test Launched
launches the Oncotype prostate cancer test, a biopsy-based test that, when combined with other clinical measures, can be used to predict the aggressiveness of a low risk prostate cancer, helping men and their doctors decide whether active surveillance or more immediate invasive treatment, such as surgery, is necessary. Read More
Oncotype Breast Cancer Test Included in Guidelines
The European Society for Medical Oncology (ESMO) includes the Oncotype Breast Cancer Assay in its treatment guidelines.
Next Generation Sequencing Program Accelerates
Next Generation Sequencing (NGS) program accelerates clinical development studies to examine both RNA-Seq expression and mutation analysis. Read More
Oncotype Breast Cancer Test for Launched
launches the Oncotype breast cancer test for patients, the first clinically validated assay to provide an individualized prediction of the 10-year risk of local recurrence to help guide treatment decision-making in patients with ductal carcinoma in situ (DCIS). Read More
Oncotype Colon Cancer Test Covered by Medicare
Medicare establishes coverage for the Oncotype colon cancer test. Read More
Oncotype Breast Cancer Test Recognized by St. Gallen Expert Consensus
The 12th St. Gallen International Breast Cancer Conference Expert Panel recognizes the Oncotype breast cancer test for its ability to provide not only prognostic, but also predictive information. Read More
International Headquarters Established
Oncotype Colon Cancer Test Launched
announces the global launch of the Oncotype colon cancer test to help patients seeking stage colon cancer treatment determine if they have aggressive disease. Read More
Oncotype Breast Cancer Test Helps More than 100,000 Patients
announces the Oncotype breast cancer test has helped guide individualized treatment decisions for more than 100,000 patients worldwide. Read More
Oncotype Breast Cancer Test Included in Guidelines
The National Comprehensive Cancer Network (NCCN) includes Oncotype in its 2008 Breast Cancer Treatment Guidelines. Read More
Oncotype Breast Cancer Test Included in Guidelines
The American Society of Clinical Oncology (ASCO) includes the Oncotype breast cancer test in its updated guidelines on the use of breast cancer tumor markers. Read More
Oncotype Breast Cancer Test Validated for Node-Positive Patients
presents positive results at from its first study investigating the Oncotype breast cancer test in node-positive breast cancer patients. Read More
Oncotype Breast Cancer Test Covered by Medicare
Medicare establishes reimbursement for the Oncotype breast cancer test for qualifying patients. Read More
Completes IPO
Oncotype Breast Cancer Test Launched
Study Validates Oncotype 21-Gene Panel
The National Surgical Adjuvant Breast and Bowel Project (NSABP) and Health, Inc. announce positive results of a new study demonstrating that the Oncotype 21-gene panel quantifies the likelihood of breast cancer recurrence for a large portion of early stage breast cancer patients, and also predicts the magnitude of chemotherapy benefit in patients from the B-20 study. Read More
Study Validates Health’s Ability to Quantify Recurrence
The National Surgical Adjuvant Breast and Bowel Project (NSABP) and Health, Inc. announces that their large, prospective B-14 clinical trial met its defined endpoints and validated that Health’s unique breast cancer assay can accurately quantify the likelihood of breast cancer recurrence in a large segment of newly diagnosed breast cancer patients. Read More
Proof of Concept Completed
completes proof of concept studies, confirming the company’s ability to successfully obtain gene expression analysis profiles from formalin-fixed paraffin-embedded (FPET) tumor tissue.
Founded in Redwood City, California
Inspired by a close friend’s cancer diagnosis, Randy Scott founds in Redwood City, California with the goal of developing high-value diagnostics to enable more personalized cancer treatment decisions based on the activity within a patient’s individual tumor.
MORE
and Oncotype – Delivering Precision Medicine
Watch how continues to transform cancer care around the world.
VIDEO
Leadership
See what’s behind our tests, which are improving treatment decisions and providing significant benefit from both a care and cost perspective.
Oncotype Products
Turning insight into action. Learn about the power of the Oncotype product portfolio.
and Oncotype – Delivering Precision Medicine
Watch how continues to transform cancer care around the world.
VIDEO
and Oncotype – Delivering Precision Medicine
Watch how continues to transform cancer care around the world.
VIDEO
Contact Us
We have offices worldwide to help you with your inquiries.
MORE
Contact Us
We have offices worldwide to help you with your inquiries.
MORE
© 2019 Health, All rights reserved.
© 2019 Health, All rights reserved.
In the and certain other jurisdictions, Health, Oncotype DX, Oncotype IQ, and Recurrence Score are registered trademarks, and Prostate Score, and AR-V7 Nucleus Detect are pending registered trademarks, of Health, Inc.
© 2019 Health, All rights reserved.Agree
does not give treatment for cancer or advise patients on their treatment plans. Anyone in doubt about their own or cancer should seek medical advice from a qualified healthcare professional.
PlaceHolder
MORE
and Oncotype – Delivering Precision Medicine
Watch how continues to transform cancer care around the world.
VIDEO
It is our mission to transform treatment decisions and outcomes in cancer by delivering clinically actionable diagnostics and services for patients.
MORE
Kim Popovits discusses devising personalized medicine in the treatment of breast cancer and colon cancer.
VIDEO
Our portfolio of tests is aimed at delivering intelligence that optimizes treatment decisions throughout the cancer patient journey.
MORE
Hear how breast cancer survivors personalized their cancer treatment with Oncotype DX.
VIDEO
is driven by the commitment to improving the lives of cancer patients.
MORE
Your Prostate Your Decision: Interview with Dan
Dan was diagnosed with early-stage prostate cancer. Watch Dan talk about his experience with the Oncotype prostate cancer test.
VIDEO
Inspired by the Life, changing work that we do? Be a part of the world's leading provider of cancer diagnostic tests.
MORE
The Brand and Company Mission
Watch Kim Popovits and others discuss the motivation, inspiration, and rewards of working at Health, as well as the company’s vision for the future.
VIDEO
Toggle Search✖
Life, Changing Careers at At Health, you have the unique opportunity to make a difference in the lives of patients with cancer, while developing your career potential. Our employees are our most valuable asset, and the individual perspectives and contributions of each person on our team are essential to our success.
Our Core Values Drive Our Culture:
Community
Winning
Why Health?
Learn about Health’s culture and why our exceptional employees are passionate about making it their mission to help cancer patients.
VIDEOS
Benefits
At Health, we value our employees and consider them an integral part of our company’s growth and success. We maintain competitive total rewards programs designed to satisfy our employees’ work life and personal life needs.
MORE
International Benefits
We recognize that to fulfill our mission worldwide, we require a diverse group of highly qualified employees. Our total rewards programs are competitive, effective, and meaningful in each country in which we do business. We're excited about the future.
MORE
Join Our Team
Be a part of the world's leading provider of cancer diagnostic tests.
Careers at Careers at © 2019 Health, All rights reserved.
© 2019 Health, All rights reserved.
In the and certain other jurisdictions, Health, Oncotype DX, Oncotype IQ, and Recurrence Score are registered trademarks, and Prostate Score, and AR-V7 Nucleus Detect are pending registered trademarks, of Health, Inc.
© 2019 Health, All rights reserved.Agree
does not give treatment for cancer or advise patients on their treatment plans. Anyone in doubt about their own or cancer should seek medical advice from a qualified healthcare professional.
PlaceHolder
MORE
and Oncotype – Delivering Precision Medicine
Watch how continues to transform cancer care around the world.
VIDEO
It is our mission to transform treatment decisions and outcomes in cancer by delivering clinically actionable diagnostics and services for patients.
MORE
Kim Popovits discusses devising personalized medicine in the treatment of breast cancer and colon cancer.
VIDEO
Our portfolio of tests is aimed at delivering intelligence that optimizes treatment decisions throughout the cancer patient journey.
MORE
Hear how breast cancer survivors personalized their cancer treatment with Oncotype DX.
VIDEO
is driven by the commitment to improving the lives of cancer patients.
MORE
Your Prostate Your Decision: Interview with Dan
Dan was diagnosed with early-stage prostate cancer. Watch Dan talk about his experience with the Oncotype prostate cancer test.
VIDEO
Inspired by the Life, changing work that we do? Be a part of the world's leading provider of cancer diagnostic tests.
MORE
The Brand and Company Mission
Watch Kim Popovits and others discuss the motivation, inspiration, and rewards of working at Health, as well as the company’s vision for the future.
VIDEO
Toggle Search✖
Benefits
Benefits | Health, Inc.
While specific components may vary by location, in general, they include:
Competitive cash compensation programs
Stock ownership opportunities including an Employee Stock Purchase Plan (ESPP)
Comprehensive healthcare coverage including medical, dental and vision
Paid time off and leaves of absences
401(k) investment plan with employer match
Non-Qualified Deferred Compensation Plan (for select employees)
Reimbursement accounts (Section 125)
Life and disability coverage
Voluntary programs including Accident and Critical Illness Insurance, Pet Insurance, Pre-Paid Legal Plan, and Group Long-Term Care Insurance Plan
Recognition programs
Community activity participation such as sports leagues, Bike to Work Day, Bring Your Child to Work Day
Training and development opportunities
Join Our Team
Be a part of the world's leading provider of cancer diagnostic tests.
and Oncotype – Delivering Precision Medicine
Watch how continues to transform cancer care around the world.
VIDEO
and Oncotype – Delivering Precision Medicine
Watch how continues to transform cancer care around the world.
VIDEO
and Oncotype – Delivering Precision Medicine
Watch how continues to transform cancer care around the world.
VIDEO
Join Our Team
Be a part of the world's leading provider of cancer diagnostic tests.
Join Our Team
Be a part of the world's leading provider of cancer diagnostic tests.
© 2019 Health, All rights reserved.
© 2019 Health, All rights reserved.
In the and certain other jurisdictions, Health, Oncotype DX, Oncotype IQ, and Recurrence Score are registered trademarks, and Prostate Score, and AR-V7 Nucleus Detect are pending registered trademarks, of Health, Inc.
© 2019 Health, All rights reserved.Agree
does not give treatment for cancer or advise patients on their treatment plans. Anyone in doubt about their own or cancer should seek medical advice from a qualified healthcare professional.
PlaceHolder
MORE
and Oncotype – Delivering Precision Medicine
Watch how continues to transform cancer care around the world.
VIDEO
It is our mission to transform treatment decisions and outcomes in cancer by delivering clinically actionable diagnostics and services for patients.
MORE
Kim Popovits discusses devising personalized medicine in the treatment of breast cancer and colon cancer.
VIDEO
Our portfolio of tests is aimed at delivering intelligence that optimizes treatment decisions throughout the cancer patient journey.
MORE
Hear how breast cancer survivors personalized their cancer treatment with Oncotype DX.
VIDEO
is driven by the commitment to improving the lives of cancer patients.
MORE
Your Prostate Your Decision: Interview with Dan
Dan was diagnosed with early-stage prostate cancer. Watch Dan talk about his experience with the Oncotype prostate cancer test.
VIDEO
Inspired by the Life, changing work that we do? Be a part of the world's leading provider of cancer diagnostic tests.
MORE
The Brand and Company Mission
Watch Kim Popovits and others discuss the motivation, inspiration, and rewards of working at Health, as well as the company’s vision for the future.
VIDEO
Toggle Search✖
Benefits
Benefits | Health, Inc.
While specific components may vary by location, in general, they include:
Competitive cash compensation programs
Stock ownership opportunities including an Employee Stock Purchase Plan (ESPP)
Comprehensive healthcare coverage including medical, dental and vision
Paid time off and leaves of absences
401(k) investment plan with employer match
Non-Qualified Deferred Compensation Plan (for select employees)
Reimbursement accounts (Section 125)
Life and disability coverage
Voluntary programs including Accident and Critical Illness Insurance, Pet Insurance, Pre-Paid Legal Plan, and Group Long-Term Care Insurance Plan
Recognition programs
Community activity participation such as sports leagues, Bike to Work Day, Bring Your Child to Work Day
Training and development opportunities
Join Our Team
Be a part of the world's leading provider of cancer diagnostic tests.
and Oncotype – Delivering Precision Medicine
Watch how continues to transform cancer care around the world.
VIDEO
and Oncotype – Delivering Precision Medicine
Watch how continues to transform cancer care around the world.
VIDEO
and Oncotype – Delivering Precision Medicine
Watch how continues to transform cancer care around the world.
VIDEO
Join Our Team
Be a part of the world's leading provider of cancer diagnostic tests.
Join Our Team
Be a part of the world's leading provider of cancer diagnostic tests.
© 2019 Health, All rights reserved.
© 2019 Health, All rights reserved.
In the and certain other jurisdictions, Health, Oncotype DX, Oncotype IQ, and Recurrence Score are registered trademarks, and Prostate Score, and AR-V7 Nucleus Detect are pending registered trademarks, of Health, Inc.
© 2019 Health, All rights reserved.Agree
does not give treatment for cancer or advise patients on their treatment plans. Anyone in doubt about their own or cancer should seek medical advice from a qualified healthcare professional.
PlaceHolder
MORE
and Oncotype – Delivering Precision Medicine
Watch how continues to transform cancer care around the world.
VIDEO
It is our mission to transform treatment decisions and outcomes in cancer by delivering clinically actionable diagnostics and services for patients.
MORE
Kim Popovits discusses devising personalized medicine in the treatment of breast cancer and colon cancer.
VIDEO
Our portfolio of tests is aimed at delivering intelligence that optimizes treatment decisions throughout the cancer patient journey.
MORE
Hear how breast cancer survivors personalized their cancer treatment with Oncotype DX.
VIDEO
is driven by the commitment to improving the lives of cancer patients.
MORE
Your Prostate Your Decision: Interview with Dan
Dan was diagnosed with early-stage prostate cancer. Watch Dan talk about his experience with the Oncotype prostate cancer test.
VIDEO
Inspired by the Life, changing work that we do? Be a part of the world's leading provider of cancer diagnostic tests.
MORE
The Brand and Company Mission
Watch Kim Popovits and others discuss the motivation, inspiration, and rewards of working at Health, as well as the company’s vision for the future.
VIDEO
Toggle Search✖
International Benefits
International Benefits | Health, Inc.
At Health, we value our employees and consider them an integral part of our company’s growth and success. We recognize that to fulfill our mission we require a diverse group of highly qualified employees. To ensure we attract, retain and motivate the people needed to carry out our mission, we review our total rewards programs regularly to make sure they're competitive, effective and meaningful in each country in which we do business. We're excited about the future.
In addition to country-specific mandated benefits, employees are eligible for plans and programs that may differ from country to country. The total rewards package includes the following components:
Canada
Stock ownership opportunities including an Employee Stock Purchase Plan (ESPP)
Extended healthcare coverage including medical and dental
Paid time off
Life and disability coverage
Supplemental healthcare coverage
Paid time off
Life and disability coverage
Stock ownership opportunities including an Employee Stock Purchase Plan (ESPP)
Paid time off
Fitness reimbursement
Recognition programs
Stock ownership opportunities including an Employee Stock Purchase Plan (ESPP)
Supplemental healthcare coverage
Paid time off
Life and disability coverage
Stock ownership opportunities including an Employee Stock Purchase Plan (ESPP)
Supplemental healthcare coverage
Paid time off
Stock ownership opportunities including an Employee Stock Purchase Plan (ESPP)
Paid time off
Stock ownership opportunities including an Employee Stock Purchase Plan (ESPP)
Paid time off
Accident and disability coverage
Stock ownership opportunities including an Employee Stock Purchase Plan (ESPP)
Supplemental healthcare coverage including medical and dental
Paid time off
Life and disability coverage
Join Our Team
Be a part of the world's leading provider of cancer diagnostic tests.
and Oncotype – Delivering Precision Medicine
Watch how continues to transform cancer care around the world.
VIDEO
and Oncotype – Delivering Precision Medicine
Watch how continues to transform cancer care around the world.
VIDEO
and Oncotype – Delivering Precision Medicine
Watch how continues to transform cancer care around the world.
VIDEO
Join Our Team
Be a part of the world's leading provider of cancer diagnostic tests.
Join Our Team
Be a part of the world's leading provider of cancer diagnostic tests.
© 2019 Health, All rights reserved.
© 2019 Health, All rights reserved.
In the and certain other jurisdictions, Health, Oncotype DX, Oncotype IQ, and Recurrence Score are registered trademarks, and Prostate Score, and AR-V7 Nucleus Detect are pending registered trademarks, of Health, Inc.
© 2019 Health, All rights reserved.